Drug Information

Drug General Information
Drug ID
D0R2OU
Former ID
DNCL001939
Drug Name
Irdabisant
Synonyms
CEP-26401
Drug Type
Small molecular drug
Indication Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10:F01-F07, F04, F05, R41.3] Phase 1 [524373]
Company
Cephalon
Structure
Download
2D MOL

3D MOL
Formula
C18H23N3O2
Canonical SMILES
CC1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3
InChI
1S/C18H23N3O2/c1-14-4-2-11-21(14)12-3-13-23-16-7-5-15(6-8-16)17-9-10-18(22)20-19-17/h5-10,14H,2-4,11-13H2,1H3,(H,20,22)/t14-/m1/s1
InChIKey
XUKROCVZGZNGSI-CQSZACIVSA-N
PubChem Compound ID
25070031
PubChem Substance ID
117638406, 134448965, 135626846, 136356707, 137264175, 141425169, 163643056, 198989058, 202535677, 224440715, 226490613, 249371974
Target and Pathway
Target(s) Histamine H3 receptor Target Info Antagonist [531661]
KEGG Pathway Neuroactive ligand-receptor interaction
Reactome Histamine receptors
G alpha (i) signalling events
WikiPathways Monoamine Transport
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 524373ClinicalTrials.gov (NCT01903824) Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects. U.S. National Institutes of Health.
Ref 531661CEP-26401 (irdabisant), a potent and selective histamine H??receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther. 2012 Jan;340(1):124-33.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.